BOTHELL, Wash., Oct. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the promotion of Henry "Rick"
Costantino, Ph.D., to Chief Scientific Officer of Delivery. Dr. Costantino
will assume the responsibilities for leading Nastech's development of new drug
delivery technologies for peptide and protein therapeutics. Paul Johnson,
Ph.D., Nastech's Chief Scientific Officer since 2003, is retiring tomorrow,
October 5, 2007, as was previously announced.
"Nastech continues to rapidly advance new technologies for the development
of non-invasive delivery options for peptide and protein therapeutics," stated
Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Rick's
promotion ensures that we will maintain strong scientific leadership and
continuity in our research efforts as we expand our capabilities in this area.
He will concentrate on advancing the development of new drugs and delivery
systems for peptide and protein drugs."
Dr. Quay added, "I would like to thank Dr. Johnson for his many years of
dedicated service to Nastech. During his tenure as Chief Scientific Officer,
Nastech's drug delivery technologies have made significant advances. We wish
Paul well in his future endeavors."
"As Chief Scientific Officer of Delivery, I am pleased to have the
opportunity to direct the outstanding pharmaceutical development team here at
Nastech to develop new approaches for the delivery of peptide and protein
drugs," stated Dr. Costantino. "My experience in the drug delivery industry
and at Nastech provides the background to support our goals as we further the
advancement of Nastech's drug delivery technologies, providing more
opportunities for patients and physicians while increasing shareholder value."
Dr. Costantino has served as Director of Formulations since June 2003 and
was recently promoted to Vice President of Pharmaceutical Research &
Development. Prior to joining Nastech, he spent five years at Alkermes, Inc.
working to develop new technologies for enhanced delivery of peptide and
protein therapeutics and served as a key member in managing external
collaborations. Prior to that, he spent three years at Genentech, Inc. as a
research scientist in their pharmaceutical research and development group.
Dr. Costantino received his Bachelor of Science and Master of Science degree
from The Johns Hopkins University and a Ph.D. in Chemical Engineering from the
Massachusetts Institute of Technology.
In Dr. Costantino's new role, he will focus on the development of
intranasal peptides and proteins. The Company's RNAi therapeutics programs
will continue under the direction of Dr. Quay.
Nastech is a biopharmaceutical company developing innovative products
based on proprietary molecular biology-based drug delivery technologies.
Nastech and its collaboration partners are developing products for multiple
therapeutic areas including osteoporosis, obesity, diabetes, autism,
respiratory diseases and inflammatory conditions. Additional information about
Nastech is available at http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results to
differ materially from those projected or suggested. Factors that could cause
actual results to differ materially from those in forward-looking statements
include, but are not limited to: (i) the ability of Nastech to obtain
additional funding; (ii) the ability of Nastech to attract and/or maintain
manufacturing, research, development and commercialization partners; (iii)
Nastech's and/or a partner's ability to successfully complete product research
and development, including preclinical and clinical studies and
commercialization; (iv) Nastech's and/or a partner's ability to obtain
required governmental approvals; and (v) Nastech's and/or a partner's ability
to develop and commercialize products that can compete favorably with those of
competitors. Additional factors that could cause actual results to differ
materially from those projected or suggested in any forward-looking statements
are contained in Nastech's most recent periodic reports on Form 10-K and Form
10-Q that are filed with the Securities and Exchange Commission. Nastech
assumes no obligation to update and supplement forward-looking statements
because of subsequent events.
Director, Investor Relations
Russo Partners LLC
Matthew Haines (Investors/Media)
SOURCE Nastech Pharmaceutical Company Inc.
CONTACT: Ed Bell of Nastech, Director, Investor Relations,
+1-425-908-3639, email@example.com; or Investors and Media, Matthew Haines of
Russo Partners, LLC, +1-212-845-4235
Web site: http://www.nastech.com